What is the 13F Pro Quality Score for IRON?

13F Pro ranks Disc Medicine, Inc. (IRON) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IRON's current score at https://13fpro.ai/research/IRON (free sign-up required for the full ranking).

Which hedge funds own the most IRON stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IRON include FMR, RA CAPITAL MANAGEMENT, L.P., BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IRON as soon as new 13F filings post.

Where does 13F Pro source IRON data?

All Disc Medicine, Inc. fundamentals and ownership data come directly from SEC EDGAR. Disc Medicine, Inc. files with the SEC under CIK 1816736. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IRON in?

Disc Medicine, Inc. (IRON) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IRON research updated on 13F Pro?

IRON's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Disc Medicine, Inc.(IRON)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1816736 IRON stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IRON Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Disc Medicine, Inc. (IRON), a Healthcare sector company. IRON is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Disc Medicine, Inc. reports net income of $-63.5M, free cash flow of $-62.2M. Top institutional holders of IRON by reported 13-F value include FMR, RA CAPITAL MANAGEMENT, L.P., BlackRock,, based on the most recent SEC filings. IRON trades on the Nasdaq exchange and files with the SEC under CIK 1816736. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Disc Medicine, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-63.5M

Free Cash Flow

Q1 2026

$-62.2M

D/E Ratio

Q1 2026

0.04

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-177.6% YoY

$-212.2MFY 2025

FY21 $-36.0MFY22 $-46.8MFY23 $-76.4MFY25 $-212.2M

Operating Income

-159.0% YoY

$-236.0MFY 2025

FY21 $-30.9MFY22 $-47.5MFY23 $-91.1MFY25 $-236.0M

EPS (Diluted)

-75.7% YoY

$-6.01FY 2025

FY21 $-40.95FY22 $-45.05FY23 $-3.42FY25 $-6.01

Total Assets

+119.3% YoY

$806.9MFY 2025

FY21 $140.4MFY22 $200.2MFY23 $368.0MFY25 $806.9M

Total Debt

$29.2MFY 2025

FY21 —FY22 —FY23 $0.00FY25 $29.2M

Op. Cash Flow

-145.6% YoY

$-180.4MFY 2025

FY21 $-27.5MFY22 $-42.3MFY23 $-73.5MFY25 $-180.4M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-212.2M -177.6%	$-76.4M -63.2%	$-46.8M -30.2%	$-36.0M +11.9%	$-40.8M	—
Operating Income	$-236.0M -159.0%	$-91.1M -91.9%	$-47.5M -53.5%	$-30.9M +9.1%	$-34.0M	—
EPS (Diluted)	$-6.01 -75.7%	$-3.42 +92.4%	$-45.05 -10.0%	$-40.95	—	—
Total Assets	$806.9M +119.3%	$368.0M +83.8%	$200.2M +42.6%	$140.4M +1588.1%	$8.3M	—
Total Debt	$29.2M	$0.00	—	—	$25.7M	—
Operating Cash Flow	$-180.4M -145.6%	$-73.5M -73.9%	$-42.3M -53.5%	$-27.5M +15.8%	$-32.7M	—

AI Insight: IRON Financial Trends

Disc Medicine remains pre-revenue with quarterly cash burn accelerating to $62M in Q1 2026, pressuring a $688M equity base.

• Operating losses widened sharply from $-31M in Q2 2024 to $-70M in Q1 2026, more than doubling over seven quarters.

• Operating cash outflow surged from $-15M in Q2 2024 to $-62M in Q1 2026, signaling accelerating cash consumption.

• Equity jumped from $444M in Q4 2024 to $660M in Q1 2025 and again to $740M in Q4 2025, indicating equity raises funding operations.

• Total debt has remained flat at $29M since Q4 2024, suggesting the company relies on equity rather than debt financing.

⚠ At $62M quarterly cash burn in Q1 2026, the $688M equity cushion implies roughly 11 quarters of runway absent new raises.

⚠ No revenue has appeared in any reported quarter; any pipeline readout triggering commercial inflection is the key catalyst to monitor.

⚠ Equity declined $52M from $740M in Q4 2025 to $688M in Q1 2026 — watch for another capital raise to sustain operations.

AI Insight: IRON Ratio Trends

Return metrics have deteriorated sharply since Q1 2025, with ROIC deepening from -23.2% to -38.7% by Q1 2026, signaling accelerating cash burn.

• ROIC deteriorated from -23.2% in Q1 2025 to -38.7% in Q1 2026, a 15.5pp worsening over four quarters.

• ROA followed the same trajectory, declining from -19.2% in Q1 2025 to -33.9% in Q1 2026.

• Leverage remains minimal with D/E stable at 0.04 in Q1 2026, unchanged from Q1 2025.

⚠ ROIC hit -45.0% in Q3 2025 — the worst reading in the dataset — before partially recovering to -38.7% in Q1 2026.

⚠ ROE has worsened from -20.6% to -36.9% over the past year; sustained deterioration would pressure equity base.

Get alerted when IRON's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Disc Medicine, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IRON

FMR LLC
$357.2M5,586,894 sh
RA CAPITAL MANAGEMENT, L.P.
$156.7M2,450,221 sh
BlackRock, Inc.
$145.4M2,273,831 sh
WELLINGTON MANAGEMENT GROUP LLP
$111.0M1,735,376 sh
STATE STREET CORP
$108.6M1,698,244 sh
Atlas Venture Life Science Advisors, LLC
$96.8M1,513,875 sh
VANGUARD CAPITAL MANAGEMENT LLC
$87.9M1,375,430 sh
Frazier Life Sciences Management, L.P.
$86.6M1,354,852 sh
TCG Crossover Management, LLC
$85.8M1,341,862 sh
BVF INC/IL
$81.4M1,272,312 sh

Fund	Value	Shares
FMR LLC	$357.2M	5,586,894
RA CAPITAL MANAGEMENT, L.P.	$156.7M	2,450,221
BlackRock, Inc.	$145.4M	2,273,831
WELLINGTON MANAGEMENT GROUP LLP	$111.0M	1,735,376
STATE STREET CORP	$108.6M	1,698,244
Atlas Venture Life Science Advisors, LLC	$96.8M	1,513,875
VANGUARD CAPITAL MANAGEMENT LLC	$87.9M	1,375,430
Frazier Life Sciences Management, L.P.	$86.6M	1,354,852
TCG Crossover Management, LLC	$85.8M	1,341,862
BVF INC/IL	$81.4M	1,272,312

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IRON on your watchlist

Track score changes the day Disc Medicine, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IRON a good stock to buy?

13F Pro's AI-powered analysis of Disc Medicine, Inc. (IRON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IRON are available on the IRON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IRON?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IRON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Disc Medicine, Inc.'s investment landscape.